UroGen Pharma URGN Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about UroGen Pharma's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is UroGen Pharma's additional paid-in capital?
- UroGen Pharma (URGN) reported additional paid-in capital of $858.9M in Q1 2026.
- How has UroGen Pharma's additional paid-in capital changed year-over-year?
- UroGen Pharma's additional paid-in capital increased by 6.9% year-over-year, from $803.47M to $858.9M.
- What is the long-term trend for UroGen Pharma's additional paid-in capital?
- Over 5 years (2020 to 2025), UroGen Pharma's additional paid-in capital has grown at a 13.5% compound annual growth rate (CAGR), from $452.53M to $854.09M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.